Plato Investment Management Ltd Takes Position in IDEXX Laboratories, Inc. $IDXX

Plato Investment Management Ltd purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 2,836 shares of the company’s stock, valued at approximately $1,484,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of IDXX. J.Safra Asset Management Corp purchased a new stake in shares of IDEXX Laboratories in the second quarter valued at about $25,000. SHP Wealth Management purchased a new position in shares of IDEXX Laboratories during the fourth quarter worth about $26,000. Elevation Wealth Partners LLC increased its position in IDEXX Laboratories by 188.2% in the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after acquiring an additional 32 shares during the period. Virtus Advisers LLC purchased a new stake in IDEXX Laboratories during the 3rd quarter valued at approximately $26,000. Finally, WealthCollab LLC purchased a new stake in IDEXX Laboratories during the 2nd quarter valued at approximately $30,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on IDXX. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. UBS Group increased their price target on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Citigroup lifted their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Barclays dropped their price objective on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Finally, Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, July 29th. Six research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $747.00.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $546.09 on Tuesday. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The stock has a 50 day simple moving average of $560.74 and a 200-day simple moving average of $579.65. The company has a market cap of $43.02 billion, a price-to-earnings ratio of 38.40, a price-to-earnings-growth ratio of 2.94 and a beta of 1.54. IDEXX Laboratories, Inc. has a 12-month low of $518.55 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The firm had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.20 billion. During the same period in the previous year, the business earned $3.50 earnings per share. The company’s revenue for the quarter was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.